Previously, we demonstrated that progesterone (P 4 ) promoted adult rat neural progenitor cell (rNPC) proliferation with concomitant regulation of cell-cycle gene expression via the P 4 receptor membrane component/ERK pathway. Here, we report the efficacy of seven clinically relevant progestins alone or in combination with 17␤-estradiol (E 2 ) on adult rNPC proliferation and hippocampal cell viability in vitro and in vivo. In vitro analyses indicated that P 4 , norgestimate, Nestorone, norethynodrel, norethindrone, and levonorgestrel (LNG) significantly increased in rNPC proliferation, whereas norethindrone acetate was without effect, and medroxyprogesterone acetate (MPA) inhibited rNPC proliferation. Proliferative progestins in vitro were also neuroprotective. Acute in vivo exposure to P 4 and Nestorone significantly increased proliferating cell nuclear antigen and cell division cycle 2 expression and total number of hippocampal 5-bromo-2-deoxyuridine (BrdU)-positive cells, whereas LNG and MPA were without effect. Mechanistically, neurogenic progestins required activation of MAPK to promote proliferation. P 4 , Nestorone, and LNG significantly increased ATP synthase subunit ␣ (complex V, subunit ␣) expression, whereas MPA was without effect. In combination with E 2 , P 4 , Nestorone, LNG, and MPA significantly increased BrdU incorporation. However, BrdU incorporation induced by E 2 plus LNG or MPA was paralleled by a significant increase in apoptosis. A rise in Bax/Bcl-2 ratio paralleled apoptosis induced by LNG and MPA. With the exception of P 4 , clinical progestins antagonized E 2 -induced rise in complex V, subunit ␣. These preclinical translational findings indicate that the neurogenic response to clinical progestins varies dramatically. Progestin impact on the regenerative capacity of the brain has clinical implications for contraceptive and hormone therapy formulations prescribed for pre-and postmenopausal women. (Endocrinology 151: 5782-5794, 2010) 
I
t is increasingly clear that gonadal hormone function extends well beyond reproduction (1) (2) (3) . In brain, progesterone (P 4 ) exerts multiple nonreproductive functions including regulating mood, inflammation, bioenergetics, neural plasticity, cognition, and recovery from traumatic brain injury (1, 2, 4 -6) . Clinically, P 4 and related synthetic progestins have been widely used as therapeutics for fertility, contraception, and hormone replacement therapy (1, 2, (7) (8) (9) (10) . The majority of progestins are derived from three tetracyclic structures: pregnane, estrane, and gonane and have varying degrees of specificity for P 4 receptors (PRs) ( Fig. 1) (9, 10) . Recently, a newer class of progestins, the 19-norprogesterone molecules, has been developed with improved progestational activity with little to no androgenic activity and used for contraception and hormone therapy (11) .
Although the effect of progestins on the reproductive system has been extensively studied, their impact on central nervous system function, particularly adult neurogenesis and cell viability, remains largely unexplored (1) . The generation of new neurons or neurogenesis in the two proliferative zones of the brain, the subgranular zone of the hippocampus and the subventricular zone of the cerebral ventricles, is the principle regenerative strategy of the adult brain. In parallel, cellular viability can be a predictive indicator of the health of newly generated and existing cells. In this study, we selected seven clinically relevant progestins as representative of three different classes of progestins to determine their effects on neural progenitor proliferation and neuronal viability ( Fig. 1) : one with pregnane structure [medroxyprogesterone acetate (MPA)], one with 19-norprogesterone structure (Nestorone), three with estrane structure [norethindrone (NET), NET acetate (NETA), and norethynodrel], and two with gonane structure [levonorgestrel (LNG) and norgestimate (NGM)]. Notably, NETA, norethynodrel, and NGM are prodrugs; the first two require in vivo conversion to NET to exert their progestational effects, whereas the latter requires conversion to LNG for activity (8, 12) .
Analyses reported here were conducted to determine the impact of clinically relevant progestins on the regenerative capacity of brain when administered alone or in combination with 17␤-estradiol (E 2 ). Results of these studies indicate that acute exposure to clinically relevant progestins and E 2 /progestin combinations differentially regulated neurogenic and neuroprotective responses in brain. The data indicate that clinical progestins vary dramatically in their impact, which can range from promoting the regenerative function of the brain to increasing cell death.
Materials and Methods

Chemicals
P 4 , NET, NETA, ORG 31710, norethynodrel, LNG, MPA, and NGM were purchased from Steraloids (Newport, RI). Nestorone was provided by Sitruk-Ware (Rockefeller University and Population Council, New York, NY).
PR, androgen receptor (AR), and glucocorticoid receptor (GR) competitive binding
The binding affinities of tested progestins to PR, AR, and GR were determined by fluorescent polarization competitive binding assays using purified baculovirus-expressed human PR/AR/GR and fluorescent P 4 /androgen/glucocorticoid ligand PL Red (Invitrogen, Grand Island, NY) as described before (7, 13) , respectively. Polarization values were determined using GENios Pro microplate reader (Tecan, San Jose, CA) and plotted against the logarithm of the concentrations of test compounds. IC 50 values were determined by nonlinear least-squares analysis.
Culture of rat neural progenitor cells (rNPCs)
Rat NPCs derived from adult rat dentate gyrus (gift from Fred Gage; Laboratory of Genetics, The Salk Institute, CA) were provided as cryopreserved cells. They were cultured as described previously (7, 13, 14) in DMEM/Hams F-12 medium (1:1; Omega Scientific, Tarzana, CA) with 1% penicillin/streptomycin/amphotericin B (Invitrogen), supplemented with N2 (1%; Invitrogen) and basic fibroblast growth factor (bFGF) (20 ng/ml; Invitrogen) in a humidified incubator (37 C and 5% CO 2 ). Cells were plated at a density of 2 ϫ e 6 cells/flask or 7.5-15 ϫ e 4 cells/well ⅐ 96-well plates.
5-Bromo-2-deoxyuridine (BrdU) incorporation
Cell proliferation was determined by S phase incorporation of BrdU. After 4 -6 h of starvation (medium without supplements), rNPCs were loaded with 10 M BrdU in the presence or absence of bFGF and varying concentrations of P 4 or test progestins in unsupplemented maintenance medium for 1d. The rNPCs were then processed as described previously (7, 14) . After subtracting the value of the blank (without BrdU loading), data were analyzed using a one-way ANOVA, followed by a Neuman-Keuls post hoc test.
Primary neuronal culture
Hippocampal neuronal cultures were prepared as previously described (13) .
Glutamate exposure and neuronal viability
Hippocampal neuronal cultures grown on 96-well culture plates for 7d in vitro were pretreated with vehicle alone or test compounds, followed by exposure to 200 M glutamate as previously described (13) . After glutamate exposure, cultures were washed with N-2-hydroxyethylpiperazine-NЈ-2-ethane sulfonic acid-buffered saline solution and replaced with fresh NBM containing the test compounds or combinations. Cultures were returned to the incubator and incubated for 24 h before analysis of neuronal viability using colorimetric lactate dehydrogenase (LDH) release in the media.
Animals
Use of animals was approved by the Institutional Animal Care and Use Committee at the University of Southern California (Protocol No. 10911). Embryonic d-18 fetuses derived from time-pregnant Sprague Dawley rats (Harlan, Indianapolis, IN) were used to obtain primary neuronal cultures for in vitro experiments. Ovariectomized (OVX) 3-month-old adult female Sprague Dawley rats (Harlan) were used for in vivo experiments. For progestin-only treatments (n ϭ 5 per group), rats were sc injected 1 wk after ovariectomy with vehicle alone or P 4 [30 g/kg body weight (BW)], Nestorone (30 g/kg BW), LNG (30 g/kg BW), and MPA (30 g/kg BW), respectively, and 1 h later with 100 mg/kg BW BrdU injection. For E 2 and progestin combined treatments (n ϭ 5 per group), rats were sc injected 1 wk after ovariectomy with either E 2 alone (30 g/kg BW), or E 2 combined with P 4 /Nestorone/LNG/MPA (30 g/kg BW), or equivalent volume of sesame oil as vehicle control, respectively, and 1 h later with 100 mg/kg BW BrdU injection. Doses of progestins were based on our previous in vivo studies, where the same P 4 treatment produced P 4 levels in rats of 28 pg/g in brain tissue and 20 pg/ml in serum (5) . Animals were killed 24 h after injection, and one hemisphere was fixed in 4% paraformaldehyde and processed for fluorescence-activated cell sorting (FACS) analysis, and whole hippocampus (both posterior and anterior hippocampus but not alveus or entorhinal/perirhinal cortex) from the other hemispheres were manually dissected for Western blot analysis.
Western blot analyses
Hippocampal samples from progestin-treated rats were assessed for protein expression of proliferating cell nuclear antigen (PCNA) (1:500; Zymed Laboratories, San Francisco, CA) and cell division cycle 2 (CDC2) or cyclin dependent kinase 1 (Cdk1) (1:500; Novus Biologicals, Littleton, CO), mitochondria complex V, subunit ␣ (CV␣) (1:1000; MitoSciences, Inc., Eugene, OR), Bax (1:1000; Cell Signaling Technology, Danvers, MA), and Bcl-2 (50E3) (1:1000; Cell Signaling Technology) by Western blotting as previously described (7, 14) . Relative amounts of protein expression were quantified by optical density analysis using UN-SCAN-IT gel automated digitizing system (Silk Scientific, Inc., Orem, UT).
Nuclei extraction and flow cytometry counting
Hippocampi were dissected from the fixed hemispheres using anatomical landmarks as described (15) . Extracted hippocampi were homogenized and nuclei sample collected into a 1.5 ml microcentrifuge tube, washed four times using 200 l of PBS, and then centrifuged for 10 min at 10,000 rpm. The pellet was then resuspended in 600 l of PBS plus 0.5% Triton X-100, heated for 1 h at 75 C for epitope retrieval, and incubated for 24 h at 4 C with primary mouse monoclonal anti-BrdU antibody (1:100, Ab12219; Abcam, Cambridge, MA) for BrdUϩ cell count or with Clontech ApoAlert DNA Fragmentation Assay kit for DNA fragmentation [terminal deoxynucleotidyltransferase-mediated 2Ј-deoxyuridine 5Ј-triphosphate nick end labeling (TUNEL)] detection. The number of nuclei was estimated by counting the propidium iodide, and the number of BrdU or TUNEL-labeled cells was detected using BD LSR II flow cytometer and BD FACSDiva software (BD Biosciences, San Jose, CA).
Statistical analyses
Data are presented as mean Ϯ SEM and statistically significant differences determined by a one-way ANOVA followed by a Student-Newman-Keuls post hoc analysis.
Results
PR/GR/AR binding profiles of clinical progestins
To determine the binding profiles of tested progestins ( Fig. 1 ) to nuclear PR (nPR), fluorescence polarizationbased competitive binding assay was conducted (7, 13 
Clinical progestin regulation of rNPC proliferation in vitro
Our previous study demonstrated that P 4 increased rNPC proliferation in a dose-dependent manner (7). To determine whether progestins exhibited comparable efficacy on rNPC proliferation, BrdU chemiluminescence ELISA was conducted and compared with the proliferative efficacy of P 4 at the same concentration (Fig. 2) . Results of these analyses indicated that at 24 h, NGM was more potent in promoting rNPC proliferation than P 4 at all concentrations, with minimal effective dose of 10 Ϫ11 M and a maximal effect of 40.4 Ϯ 1.5% increase at 10 Ϫ9 M (P Ͻ 0.001). Nestorone and P 4 were equally efficacious at their EC 100 concentrations, with both EC 100 values being 10 Ϫ10 M. Norethynodrel induced a comparable effect with P 4 within the picomolar to low nanomolar range and was significantly (P Ͻ 0.005) more efficacious than P 4 at high nanomolar to micromolar range, with minimal effective dose at 10 Ϫ11 M and maximal effective effect (43.5 Ϯ 3.7% increase) at 10 Ϫ7 M. NET induced a moderate effect in promoting rNPC proliferation but was less effective than P 4 with a minimally effective dose of 10 Ϫ11 M and a maximal effect was 21.8 Ϯ 1.7% increase at 10 Ϫ6 M. Similarly, LNG exhibited a minimally effective dose of 10 Ϫ8 M and a maximal effect of 17.7 Ϯ 0.8% at 10 Ϫ7 M. NETA and ORG 31710 exerted no effect on rNPC proliferation at all concentrations except 10 Ϫ5 M, a concentration at which rNPC proliferation was significantly inhibited (P Ͻ 0.05 and P Ͻ 0.01, respectively). Lastly, MPA significantly inhibited rNPC proliferation at multiple concentrations with maximal inhibition at 10 Ϫ10 M to 10 Ϫ5 M with rNPC proliferation reduced by 17.0 Ϯ 1.3% (P Ͻ 0.05) and 17.8 Ϯ 1.2% (P Ͻ 0.05), respectively.
Progestin-induced cell proliferation is dependent on ERK signaling pathway and independent of nPR
Previously we demonstrated that P 4 -induced cell proliferation is an ERK signaling pathway-dependent process (7). To determine whether ERK activation was required for progestin-induced cell proliferation, BrdU chemiluminescence ELISA was conducted in the presence or absence of the MEK kinase inhibitor UO126 (Fig. 3A) . Consistent with results in Fig. 2 , at 10 Ϫ8 M, both P 4 and Nestorone significantly increased BrdU incorporation by 14.6 and 16.4% compared with vehicle control, respectively (P Ͻ 0.0001 and P Ͻ 0.0001, respectively). At 10 Ϫ8 M, LNG had no statistically significant effect, although a positive trend was observed, whereas MPA significantly inhibited BrdU incorporation (P Ͻ 0.05). Inhibition of ERK/MAPK signaling pathway by UO126 abolished P 4 -induced cell proliferation (P Ͻ 0.0001), which replicated our previous findings (7), and completely inhibited the proliferative effects of Nestorone and LNG (P Ͻ 0.0001 and P Ͻ 0.05, respectively) with no effect observed on MPA-induced inhibition of cell proliferation. These data indicate that like P 4 , Nestorone-induced, and LNG-induced cell proliferation require the ERK signaling pathway, whereas the inhibitory effect of MPA is independent of the ERK/MAPK signaling pathway. Analysis of the structure-activity relationship (SAR) was conducted to determine structural molecular features required for proliferative efficacy of clinical progestins. The presence of an acetyl or hydroxyl group at the 17S-position of the D ring was favorable for rNPC proliferation, whereas a methyl group at the 6-position, whether it was in the R or S configuration, negatively impacted cell proliferation (Fig. 3B) . A modification at the 10R-position or at the 13S-position had no effect on the proliferative capabilities of the molecule nor did the position of the double bond between C-4 and C-5 or between C-5 and C-10. Interestingly, addition of a hydroxyl group at the C-17-position is known to eliminate the progestational effect of progestins, whereas acetylation of the C-17-OH can reverse this effect to render the progestins orally active.
Addition of the 13-C ethyl group is positively associated with the highest progestational activity, consistent with findings that helix 12 Met909 is the key residue for PR activation by both testosterone-derived and P 4 -derived progestins with a 13-methyl or a 13-ethyl substitutions ), and bFGF was used as positive control. At each concentration, the proliferative efficacies of progestins (solid lines) were compared against that of P 4 (dotted line). A-C, Effects of progestins that had greater proliferative efficacy relative to P 4 . D and E, Progestins with lower proliferative efficacy relative to P 4 . F-H, Progestins with no or antagonizing effects on cell proliferation. Data are derived from three independent assays, analyzed using one-way ANOVA, followed by Neuman-Keuls post hoc test, and plotted as percentage increase vs. vehicle control (mean Ϯ SEM). *, P Ͻ 0.05; **, P Ͻ 0.01; ***, P Ͻ 0.005; and ****, P Ͻ 0.001 vs. vehicle control. (17) . Surprisingly, modifications favoring the proliferative effect of the progestins are negatively correlated with their binding affinity to nPR. Thus, it is likely that the proliferative effects of progestins are not mediated by nPR, which is consistent with our previous finding that nPR is not expressed in rNPCs, that the proliferative effect of P 4 in rNPCs is not mediated by nPR but is instead mediated by the membrane PR membrane component 1 (PGRMC-1) (7).
Clinical progestin regulation of neuroprotection in vitro
Previous analyses indicated that P 4 exerted significant neuroprotection against neurodegenerative insults (5, 18) . We therefore determined whether clinical progestins exerted comparable efficacy in protecting primary hippocampal neurons against degeneration induced by excitoxic glutamate. LDH release in the culture medium served as an indicator of neuronal membrane integrity, a minimum requirement for neuroprotection (13) . Dose-response analysis was conducted for each progestin (Fig. 4) LNG also induced maximal neuroprotection of 39.6 Ϯ 3.2% (P Ͻ 0.001). In contrast, NGM was much less potent with neuroprotection at 10 Ϫ7 M, whereas both MPA and NET showed modest neuroprotection at 10 Ϫ11 M but were without effect at other concentrations. Similar to the results of clinical progestin regulation of rNPCs proliferation, no association was found between the neuroprotective efficacy of the progestins and their binding affinities to PR, AR, or GR.
Clinical progestins regulate neurogenic activity and cell viability in vivo
To determine the generalizability of in vitro findings to the in vivo condition, analyses of rNPC proliferation and cell viability were conducted in 3-month-old Sprague Dawley OVX female rats treated with selected progestins. Selection of progestins for in vivo testing was based on the requirement that the progestin exert both a significant increase in rNPC proliferation and neuroprotection. Among these progestins, Nestorone, norethynodrel, and LNG fulfilled these criteria. However, norethynodrel was not advanced to in vivo testing because of its aromatization in liver to form the potent estrogen ethinyl-estradiol (19) and thus potential involvement of ER in proliferative action in vivo could not be excluded. Although MPA exerted a decrease in both rNPC proliferation and neuroprotection, it was included for in vivo analysis based on its continued clinical use and its controversial effects in brain (5, 20, 21) . In addition to FACS determination of total number of BrdUϩ hippocampal cells, two cell cycle protein markers, PCNA, which is associated with transition through S phase, and CDC2 (CDK1), which is associated with transition through the mitotic M phase, were assessed (7, 14) . Results of cell cycle protein expression as determined by Western blotting indicated that both P 4 and Nestorone   FIG. 3 . Progestin-induced cell proliferation is dependent on MAPK and independent of cPR. A, BrdU chemiluminescence ELISA was carried out to determine the signaling cascade of progestin-induced cell proliferation. Rat NPCs were starved for 4 h before exposure to 100 pM progestin alone or progestin combined with MAPK inhibitor UO126 (100 nM) for 24 h, and cell proliferation was evaluated by BrdU chemiluminescence ELISA measuring BrdU incorporation. Ethanol ϩ DMSO (1 ϫ e Ϫ6 ) was used as vehicle control, and bFGF was used as positive control. Data were collected from four independent assays, analyzed using one-way ANOVA, followed by Neuman-Keuls post hoc test, and plotted as percentage increase vs. vehicle control (mean Ϯ SEM). *, P Ͻ 0.05; **, P Ͻ 0.01; ***, P Ͻ 0.005; and ****, P Ͻ 0.0001 vs. vehicle control; †, P Ͻ 0.05; † † † †, P Ͻ 0.001 vs. progestinalone group. B, Structure-activity analysis of progestin-induced proliferative effects. Critical structural features of progestins required for proliferative effects from SAR analysis.
Endocrinology, December 2010, 151(12):5782-5794 endo.endojournals.org 5787 significantly increased PCNA expression at the protein level (P Ͻ 0.05 and P Ͻ 0.01, respectively) ( Fig. 5A) , whereas LNG and MPA had no significant effect upon PCNA protein expression (P ϭ 0.15 and P ϭ 0.08, respectively) (Fig. 5A, top) . CDC2 protein expression was significantly increased by P 4 and Nestorone (P Ͻ 0.05 and P Ͻ 0.01, respectively), whereas LNG and MPA had no significant effect on CDC2 protein expression (P ϭ 0.07 and P ϭ 0.23, respectively) (Fig. 5A, bottom) .
To assess the total number of BrdUϩ cells, the contralateral hippocampal hemisphere used for protein analysis was fixed and processed for FACS analysis. Total number of BrdUϩ cells per each hippocampus was determined and normalized to that of vehicle control. Results were plotted as the percent increase in BrdUϩ cell ratio compared with vehicle control (Fig. 5B) . Results derived from FACS analysis indicated that P 4 and Nestorone significantly increased BrdUϩ cell number (P Ͻ 0.05 and P Ͻ 0.01, respectively), whereas LNG induced a comparable increase in BrdU incorporation with P 4 but was not statistically significant (P ϭ 0.054). Further, MPA, which inhibited rNPC proliferation in vitro, had no significant effect on rNPC proliferation in vivo. Results of FACS analyses are consistent with data derived from Western blot analyses.
Previous analyses demonstrated that P 4 increased cell viability by promoting mitochondrial function and reducing oxidative damage (4). As a marker of cell viability, expression of the ␣-subunit of ATP synthase-complex V (CV␣) of the mitochondrial oxidative phosphorylation pathway was assessed by Western blot analysis. Consistent with previous results (4), P 4 significantly increased CV␣ expression in vivo by 1-to 2-fold (P Ͻ 0.05) (Fig. 5C ). Nestorone and LNG also significantly increased CV␣ expression in vivo (P Ͻ 0.01 and P Ͻ 0.05 compared with vehicle control, respectively) (Fig. 5C ), whereas MPA ex-
FIG. 5.
Progestin regulation of neurogenic and neuroprotective activity in the hippocampus of OVX adult female rat. P 4 , Nestorone, LNG, and MPA were selected for in vivo efficacy assessment for their regulation of neurogenic activity; 30 g/kg BW progestins were injected to 3-monthold OVX female rat followed by BrdU injection 1 h later. A, Effect of tested progestins on cell proliferation marker PCNA and CDK1 protein level in the hippocampus. B, Progestin regulation of BrdUϩ cell count in the hippocampus of OVX adult female rat. *, P Ͻ 0.05 and **, P Ͻ 0.01 compared with vehicle control. C, left, Effects of progestins on CV␣ expression in rat hippocampus at protein level. Right, Effects of progestins on Bax/Bcl-2 expression ratio at protein level. P Ͻ 0.05 and P ϭ 0.08, respectively.
Endocrinology, December 2010, 151(12):5782-5794 endo.endojournals.org 5789 erted no significant effect on CV␣ expression level, although a trend toward a decrease was observed (P ϭ 0.18). One of the closely associated events of increased cell viability is decreased apoptosis. To determine the effects of progestins on apoptosis, Western blot analyses were conducted to determine the expression level of Bax, a mediator of apoptosis by translocating to the mitochondria to release apoptotic factors such as cytochrome c (22), and Bcl-2, an antiapoptotic protein that is a key component of the neuroprotective effect of E 2 (22) . Ratio of Bax to Bcl-2 was used as the indicator of in vivo apoptotic activity, because it positively correlates with apoptosis. P 4 and Nestorone had no effect on the ratio of Bax/Bcl-2 expression, whereas LNG (P Ͻ 0.05) and MPA (P ϭ 0.05) significantly increased Bax/Bcl-2 ratio consistent with its proapoptotic effect in uterus reported by other groups (23) (24) (25) . Together with previous results on CV␣ expression, the in vitro neuroprotective efficacy of clinical progestins paralleled their efficacy in vivo to induce markers of cell viability.
Impact of clinical progestins in combination with E 2 on neurogenesis and cell viability in vivo
When used clinically for hormone replacement therapy/ contraceptive therapy, progestins are administered in conjunction with an estrogen. To determine the impact of the combination of E 2 and clinical progestins on neurogenesis and cell viability in vivo, young adult OVX female Sprague Dawley rats were divided into six groups and received sc injection with either E 2 alone (30 g/kg BW) or E 2 combined with either P 4 , Nestorone, LNG, MPA (30 g/kg BW), or equivalent volume of sesame oil as vehicle control. Hippocampi were isolated 24 h later for Western blot analysis and flow cytometry to determine the impact of treatment on cell viability and neurogenesis, respectively.
Expression level of PCNA, which is associated with transition through S phase, was assessed to determine the impact of treatment groups on the entry into the cell cycle required for neurogenesis. Results of these analyses indicated that E 2 significantly increased PCNA expression at the protein level, and combination of E 2 and progestins were progestin dependent (Fig. 6A ): E 2 ϩNestorone induced the greatest magnitude of PCNA expression (P Ͻ 0.01), whereas E 2 ϩP 4 , E 2 ϩLNG and E 2 ϩMPA exhibited comparable increase in PCNA level (P Ͻ 0.05). Further, E 2 ϩNestorone-induced PCNA expression was significantly greater when compared with E 2 alone (P Ͻ 0.05). Entry into the cell cycle was confirmed by FACS analysis, which detected BrdU incorporation in the contralateral hippocampal hemisphere (Fig. 6B) . Consistent with PCNA expression, E 2 and its combination with progestins significantly increased the BrdUϩ cell population. In contrast to the effect of MPA in vitro, where MPA inhibited rNPC proliferation, and in vivo, where it had no effect on PCNA expression or BrdU incorporation as detected by FACS, the E 2 ϩMPA group exhibited the greatest increase in the number of BrdUϩ cells indicated by a significant 4-fold increase compared with vehicle control (P Ͻ 0.01) and a 1-fold increase when compared with that of E 2 -alone group (P Ͻ 0.05). Because neither LNG nor MPA induced a rise in PCNA, CDC2, or BrdU incorporation when administered in the absence of E2, we determined whether the rise in BrdU induced by these progestins in the presence of E2 was associated with an increase in apoptosis.
To address this issue, analysis of cell viability and apoptosis were conducted. Indicators of cell viability were expression of mitochondrial ATP synthase subunit CV␣ expression and Bax/Bcl-2 ratio (Fig. 6, C and D) . Consistent with previous analyses, E 2 increased cell viability by promoting mitochondrial function and reducing oxidative damage (26), E 2 significantly increased CV␣ protein expression relative to vehicle control (Fig. 6C ). E 2 ϩP 4 significantly increased CV␣ expression comparable with that of E 2 -alone group, whereas E 2 ϩNestorone and E 2 ϩLNG significantly decreased CV␣ protein expression relative to E2 alone. Remarkably, E 2 ϩMPA significantly reduced CV␣ expression below that expressed in response to either vehicle or E 2 (P Ͻ 0.05 and P Ͻ 0.01, respectively) (Fig.  6C) . In parallel, E 2 significantly decreased the apoptosis indicator Bax/Bcl-2 ratio, whereas E 2 ϩNestorone, or LNG or MPA, increased the Bax/Bcl-2 ratio relative to E 2 alone, although the increase did not exceed the vehicle (Fig. 6D) . These results are consistent with previous reports from our group and others indicating a lack of synergy in the neuroprotective effects when P 4 and E 2 were administered in combination (18, 27) and that MPA could inhibit E2-induced neuroprotective effect by antagonizing E 2 -induced attenuation of intracellular calcium concentration (5, 18, 21) .
The rise in the Bax/Bcl2 ratio relative to E 2 suggested the potential of an apoptotic effect. To determine whether a rise in apoptosis paralleled the rise in Bax/Bcl2 ratio, TUNEL labeling was performed to identify apoptotic nuclei in response to different treatments of E 2 and progestins (Fig. 6E) , and TUNELϩ cell numbers were detected via flow cytometry analysis. Results of the FACS analysis indicated that treatment with either E 2 alone, E 2 ϩP 4 , or E 2 ϩNestorone had no effect on TUNELϩ cell number relative to vehicle-treated animals. In contrast, E 2 ϩLNG induced a 4-and a 2-fold increase in the number of TUNELϩ cells relative to vehicle and E 2 -alone group, respectively (P Ͻ 0.01 and P Ͻ 0.05). The magnitude of TUNELϩ cells was maximal in the hippocampi derived from E 2 ϩMPA-treated animals. E 2 ϩMPA-treated animals exhibited an 8-and a 4-fold increase in TUNELϩ cell count relative to vehicle and E 2 -alone group, respectively (P Ͻ 0.01 and P Ͻ 0.01). This is consistent with the proapoptotic effect of LNG and MPA in the uterus (23) (24) (25) . Collectively, these data indicate that clinical progestins can exert significantly different outcomes on the survival of proliferating NPCs in vivo.
FIG. 6.
Combined effect of E 2 and progestin on neurogenic activity and apoptosis in vivo. Vehicle, 30 g/kg BW E 2 , and 30 g/kg BW progestins combined with 30 g/kg BW E 2 were injected to 3-month-old OVX female rat followed by BrdU injection 1 h later. A, Effects of E 2 and E 2 ϩ progestins on PCNA expression level in hippocampus. B, Combined effect of E 2 ϩ progestin in regulating BrdUϩ cell count in the hippocampus of OVX adult female rat. *, P Ͻ 0.05 and **, P Ͻ 0.01 compared with vehicle control; †, P Ͻ 0.05 compared with E 2 -alone group. C, Effects of E 2 and E 2 ϩ progestins on CV␣ expression at protein level. Western blot analysis was conducted on protein isolated from hippocampus. D, Effects of E 2 and E 2 ϩ progestins on Bax/ Bcl-2 expression at protein level. E, Combined effect of E 2 ϩ progestin in regulating TUNELϩ cell count in the hippocampus of OVX adult female rat. *, P Ͻ 0.05 and **, P Ͻ 0.01 compared with vehicle control; †, P Ͻ 0.05 and † †, P Ͻ 0.01 compared with E 2 group. Endocrinology, December 2010, 151(12):5782-5794 endo.endojournals.org 5791
Discussion
In the present study, we conducted comparative analyses of seven clinically relevant progestins to determine their neurogenic and neuroprotective efficacy both in vitro and in vivo, as well as their efficacy in regulating neurogenesis and cell viability in vivo when coadministered with E 2 . Results of these analyses indicated that clinical progestins exert a range of effects that span promotion of neurogenesis and neuroprotection to inducing apoptosis and reduced cell viability. P 4 , the endogenous regulator of P 4 action promoted neurogenesis and neuroprotection served as the comparator positive control. Four of the seven clinical progestins exerted an increase of rNPC proliferation in vitro and were also neuroprotective. In vivo analyses indicated that when administered alone, P 4 and the clinical progestin Nestorone significantly increased rNPC proliferation; and Nestorone and LNG increased CV␣ expression with an efficacy comparable with or greater than P 4 . MPA was without effect in both neurogenesis and cell viability measurements. When coadministered with E 2 , P 4 , Nestorone, LNG, and MPA increased entry into cell cycle, whereas LNG and MPA increased apoptosis in parallel. The induction of apoptosis by LNG and MPA is consistent with their antagonism of E 2 -induced increase in CV␣ expression and decrease in Bax/Bcl-2 ratio.
As an initial comparative approach for the in vivo experiments, we used comparable doses of all progestins based on an effective dose of P 4 to induce rNPC proliferation in vivo. The dose of P 4 used in this study translates into a concentration of 20 pg/ml in serum (21) , comparable with that of P 4 in woman's brain during follicle phase but much lower than luteal phase (10 -30 ng/ml) or pregnancy (50 ng/ml). Thus the effects of progestins at the tested concentration are within clinically relevant range. However, uterine bioassays of the progestational activity of these progestins in uterus indicate substantially different dose response profiles (8, 12) . Further analyses are required to investigate the impact of comparatively equivalent doses of the progestins based on their progestational potency in human uterus.
Progestin regulation of neurogenic activity and cell viability in vitro and in vivo
A major finding of our analysis was that similar to P 4 , progestins can regulate rNPC proliferation in a dose-dependent manner. Among the seven progestins tested, NGM, Nestorone, norethynodrel, NET, and LNG increased BrdU incorporation comparable with that of P 4 , NETA exhibited no effect on rNPC proliferation, whereas MPA significantly inhibited rNPC proliferation. Further, the prodrugs norethynodrel and NGM were significantly more potent than their active metabolites, NET and LNG, respectively, indicating that conversion to active metabolites and binding to nPR were not required for their in vitro proliferative action. Consistent with our previous findings (7), proliferation induced by clinical progestins was dependent on the ERK signaling pathway and independent of nPR binding affinity as evidenced by further SAR analysis. Interestingly, MPA-induced inhibition of cell proliferation was not dependent on MAPK/ERK signaling pathway, because coadministration of UO126 had no impact on MPA-induced inhibition. This could be explained by our previous finding that MPA-induced pERK is not translocated to the nucleus (18, 28) , indicating that signaling pathways other than the ERK may mediate the inhibitory effect of MPA.
A likely PR candidate for mediating rNPC proliferation is the membrane-associated PGRMC-1. Our previous report demonstrated that P 4 significantly increased rNPC proliferation in a PGRMC-1 and MAPK-dependent manner (7) . SAR analysis highlighted several critical structures for their proliferative efficacy of clinical progestins, and those structural features revealed no clear association with other binding affinity to nPR. The lack of an effect of the pure nPR agonist ORG 31710 supports the postulate that nPR was not the mediator of the proliferative effect of progestins. It is possible, however, that the proliferative effects of the progestins were combined effects of binding to multiple receptors rather than one. Indeed, as reported herein and by others, LNG and NGM exerts androgenic effects by binding to and activating the nuclear AR. However, NGM in contrast with LNG inhibited nuclear translocation of the AR, revealing an antiandrogenic property (29) . Also norethynodrel induces estrogenic activity through aromatization in vivo. Although Nestorone can bind to the nuclear GR, it showed no glucocorticoid activity in vivo (16, 30, 31) . In addition, nPR is expressed in the dentate gyrus of hippocampus, and activation of nPR by P 4 is known to inhibit cell proliferation under various conditions (1) . Further, the effects of progestins on glial cell population and potential glial-neuronal cross talk remained undetermined.
An increase in neural responses induced by selected progestins was also evident in vivo. Consistent with their in vitro proliferative effects, P 4 and Nestorone significantly increased cell cycle protein expression and BrdUϩ cell number in FACS analyses compared with vehicletreated animals. The profile for LNG was consistent in that LNG failed to increase PCNA/CDC2 expression or total BrdUϩ cell number as determined by FACS analysis. Although the lineage of the newly generated cells remains to be determined, these data provide preclinical evidence that clinically relevant progestins could significantly impact the regenerative capability of the brain.
The in vitro and in vivo neuroprotective effect of P 4 has been reported by multiple groups (2, 4, 5, 20) . Results from the current analyses extend these findings to now include up-regulation of a key marker of mitochondrial function and cell viability in vivo. Further, our results demonstrate that clinically relevant progestins can differentially regulate neuron survival and viability. In vitro, norethynodrel, Nestorone, and LNG protected rat primary hippocampal neurons against glutamate-induced toxicity, whereas NGM, NET, and MPA exerted no significant effect. The lack of neuroprotective capability of MPA is consistent with our previous report (18, 32) . In vivo analyses confirmed that P 4 , Nestorone, and LNG induced a significant rise in CV␣ expression, whereas MPA showed no effect, indicating the neuroprotective effects of the progestins are closely related to their ability in regulating mitochondria function. In addition, only LNG and MPA significantly increased Bax/Bcl-2 ratio, which is consistent with previous report that P 4 does not directly regulate apoptosis, whereas both LNG and MPA induce a proapoptotic effect in the uterus (23) (24) (25) .
Combined E 2 and clinical progestin regulation of neurogenic activity and cell viability
It is well documented that E 2 promotes neurogenesis and protection against neurodegenerative insults (33) . Reported here, 30 g/kg BW E 2 significantly increased both PCNA expression level and BrdUϩ cell number at a magnitude comparable with that of P 4 alone. No significant differences were observed between E 2 -alone, E 2 ϩP 4 , and E 2 ϩNestorone group. This is in contrast with previous reports from Tanapat et al. (27) , where P 4 administration subsequent to estradiol exposure decreased the amplitude of E 2 -induced increase in BrdUϩ cell count. However, this could be explained by the differences in the treatment paradigm; Tanapat et al. (27) used chronic E 2 exposure followed by P 4 administration, whereas in our study, E 2 and P 4 treatment administration was acute and simultaneous. Further, there was no synergy in E 2 ϩP 4 -induced response compared with E 2 or P 4 alone. This is consistent with our previous report of a lack of synergy when P 4 and E 2 were administered in combination (18, 28) .
Both LNG and MPA increased BrdUϩ cell count when administered in combination with E 2 . However, in parallel to the increase in BrdUϩ cells, LNG and MPA significantly increased the number of TUNELϩ cells indicative of increased apoptosis, which is consistent with the proapoptotic effects of LNG and MPA in the uterus (23, 24) . Although the phenotype of the apoptotic cells remains unidentified at this point, it is probable that the increase of TUNELϩ cell population reflects the premature death of the newly generated cells (BrdUϩ cells).
Therapeutic implications of progestin regulation of neural proliferation and viability
Clinical progestins are an integral constituent of oral contraceptive therapy, progestin-only contraception, fertility therapy, and postmenopausal hormone therapies. Progestin containing contraceptives account for an increasing proportion of modern contraceptive formulations used by women around the world. In the United Kingdom, the progestins mainly used are 19-nortestosterone derivatives (NETA, norgestrel, and LNG) (8, 34) . In France, micronized P 4 and 19-norprogesterone (such as promegestone and nomegestrol acetate) are commonly prescribed, whereas MPA is the most prescribed progestin in the United States and the progestin used in commonly randomized controlled hormone therapy trials including the Women's Health Initiative (35) and Women's Health Initiative Memory Study (36) . Typically, clinical progestins are chronically administered extending over many years to decades. For example, depomedroxyprogesterone acetate, a long-acting formulation of MPA, is extensively prescribed for adolescent females (37) , and Norplant implant delivers constant infusion of LNG for 5-7 yr (38) . Although data contained herein are derived from acute in vitro and in vivo exposures, our emergent findings suggest that chronic use could have long-term implications for neural function, regenerative capacity, and viability. Although the impact of chronic exposure to clinical progestins remains undetermined, the acute in vivo data indicate that P 4 and Nestorone have potential beneficial outcomes for inducing and sustaining regenerative capacity of the brain. In contrast, LNG and MPA could have potential adverse outcomes on regenerative capacity of the brain.
Collectively, results of these preclinical translational analyses indicate that clinical progestins vary dramatically in their impact on the regenerative capacity of the brain and thus are likely to have clinical implications for longterm neurological function.
